Teva reaches settlement in ProAir HFA patent case

JERUSALEM — Teva has reached a settlement with Perrigo Pharmaceutical and Catalent Pharma Solutions with respect to four patents for Teva’s ProAir HFA (albuterol sulfate) Inhalation aerosol product.



This settlement provides a license to Perrigo and Catalent to sell limited units of Perrigo’s generic version of the product for an initial period beginning Dec. 19, 2016 and lasting until June 2018, when the limits will no longer apply.



There are currently no additional challenges to the IP for ProAir HFA and no further litigation pending. Teva stated that it will continue to “vigorously” defend its intellectual property rights relating to its products.